NASDAQ:CARA Cara Therapeutics (CARA) Stock Price, News & Analysis $4.65 +0.05 (+1.09%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Cara Therapeutics Stock (NASDAQ:CARA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cara Therapeutics alerts:Sign Up Key Stats Today's Range$4.51▼$4.7950-Day Range$3.00▼$6.1252-Week Range$2.71▼$13.80Volume11,265 shsAverage Volume319,720 shsMarket Capitalization$21.25 millionP/E RatioN/ADividend YieldN/APrice Target$27.84Consensus RatingHold Company OverviewCara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Read More… Cara Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks85th Percentile Overall ScoreCARA MarketRank™: Cara Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 171st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingCara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageCara Therapeutics has received no research coverage in the past 90 days.Read more about Cara Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cara Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.73% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently decreased by 56.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.39 Percentage of Shares Shorted3.73% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently decreased by 56.71%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News SentimentN/A News SentimentCara Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cara Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for CARA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows3 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cara Therapeutics' insider trading history. Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARA Stock News HeadlinesCara Therapeutics regains Nasdaq complianceJanuary 18 at 5:20 PM | msn.comCARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARAJanuary 6, 2025 | businesswire.comDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.January 21, 2025 | Brownstone Research (Ad)Cara Therapeutics Shares Rise 20% Following Reverse Stock SplitJanuary 1, 2025 | marketwatch.comCara shares jump 32% following reverse stock splitJanuary 1, 2025 | msn.comCara Therapeutics trading halted, news pendingDecember 31, 2024 | markets.businessinsider.comCara Therapeutics, Inc.: Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock SplitDecember 27, 2024 | finanznachrichten.deCara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock SplitDecember 27, 2024 | globenewswire.comSee More Headlines CARA Stock Analysis - Frequently Asked Questions How have CARA shares performed this year? Cara Therapeutics' stock was trading at $6.12 on January 1st, 2025. Since then, CARA shares have decreased by 24.0% and is now trading at $4.65. View the best growth stocks for 2025 here. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) posted its earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($4.44) EPS for the quarter, missing analysts' consensus estimates of ($3.24) by $1.20. The biopharmaceutical company earned $0.99 million during the quarter, compared to analyst estimates of $1.26 million. Cara Therapeutics had a negative net margin of 1,099.76% and a negative trailing twelve-month return on equity of 367.97%. When did Cara Therapeutics' stock split? Cara Therapeutics shares reverse split on Tuesday, December 31st 2024. The 1-12 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA). Company Calendar Last Earnings8/14/2024Today1/21/2025Next Earnings (Estimated)3/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$27.84 High Stock Price Target$60.00 Low Stock Price Target$12.00 Potential Upside/Downside+498.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($21.0084) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,510,000.00 Net Margins-1,099.76% Pretax Margin-1,099.76% Return on Equity-367.97% Return on Assets-107.43% Debt Debt-to-Equity RatioN/A Current Ratio4.77 Quick Ratio4.71 Sales & Book Value Annual Sales$20.97 million Price / Sales1.01 Cash FlowN/A Price / Cash FlowN/A Book Value$12.58 per share Price / Book0.37Miscellaneous Outstanding Shares4,570,000Free Float4,427,000Market Cap$21.25 million OptionableOptionable Beta0.51 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:CARA) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARA Stock Alerts